LP-184/STAR-001 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

20,267 results for “LP-184/STAR-001”

Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial Targeting ATRT

FDA Clears Phase 1 Pediatric CNS Cancer Trial for STAR-001 Combination Therapy

FDA Actions in October 2024 Accelerate Oncology Treatment Advances

Lantern Pharma's LP-300 Harmonic Trial Shows 86% Clinical Benefit; LP-184 Receives FDA Fast Track for Glioblastoma

Lantern Pharma Reports Strong Clinical Results and AI Platform Advancements in 2024 Year-End Update

LP-184 Receives FDA Fast Track Designation for Triple Negative Breast Cancer

FDA Grants Fast Track Designation to Lantern Pharma's LP-184 for Glioblastoma

Lantern Pharma's LP-184 Demonstrates Significant Survival Benefits in Pediatric Brain Cancer Models

Lantern Pharma Secures USPTO Notice of Allowance for Biomarker-Guided Patent on LP-184 in Multiple Solid Tumors

Lantern Pharma's LP-184 Receives FDA Fast Track for Glioblastoma Treatment

Page 1 of 258